245 related articles for article (PubMed ID: 17471008)
1. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Akiba T
Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
[TBL] [Abstract][Full Text] [Related]
2. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Tentori F; Hunt WC; Stidley CA; Rohrscheib MR; Bedrick EJ; Meyer KB; Johnson HK; Zager PG;
Kidney Int; 2006 Nov; 70(10):1858-65. PubMed ID: 17021609
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
4. [New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].
Bover J; Ballarín J; Andrés E; Ortiz-Herbener F; Barceló P
Nefrologia; 2005; 25 Suppl 2():109-16. PubMed ID: 16050413
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
[TBL] [Abstract][Full Text] [Related]
6. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
10. Calcimimetics versus vitamin D: what are their relative roles?
Drüeke TB
Blood Purif; 2004; 22(1):38-43. PubMed ID: 14732810
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
13. New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
Cannata-Andía JB; Rodriguez-García M; Román-García P; Tuñón-le Poultel D; López-Hernández F; Rodríguez-Puyol D
Pediatr Nephrol; 2010 Apr; 25(4):609-16. PubMed ID: 20151157
[TBL] [Abstract][Full Text] [Related]
14. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.
Cozzolino M; Galassi A; Gallieni M; Brancaccio D
Curr Vasc Pharmacol; 2008 Apr; 6(2):148-53. PubMed ID: 18393917
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
[TBL] [Abstract][Full Text] [Related]
17. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
[TBL] [Abstract][Full Text] [Related]
18. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
19. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
20. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]